Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 4 Issue 8

Non Waldenstrom Macroglobulenemia Igg Secreting Lymphoplasmacytic Lymphoma - A Diagnostic Challenge

Himanshu Rohela1*, Sameer Tulpule2, Nevitha Athikhari3, Deepthi Murthy4 and Raj H Vhatkar1

1Department of Orthopaedic Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
2Department of Haematooncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
3Department of Histopathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
4 Department of Histopathology, Dr Lal Path Paths, National Reference Laboratory, Delhi, India

*Corresponding Author: Himanshu Rohela, Department of Orthopaedic Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.

Received: May 20, 2020; Published: July 28, 2020



 Lymphoplasmacytic lymphoma (LPL) is a low-grade, B-cell neoplasm composed of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that typically involve the bone marrow, and it is associated with an immunoglobulin M (IgM) gammopathy. The diagnosis of LPL itself can be challenging because LPL lacks disease-specific morphologic, immunophenotypic, and genetic features to differentiate it from other mature B-cell neoplasms. Although most cases of LPL are IgM secreting, there are exceptions of rare, primary, lymph node-based presentations of LPL or lymphoplasmacytic B-cell proliferations in the bone marrow associated with IgA or IgG gammopathies. We hereby report a case of IgG secreting lymphoplasmacytic lymphoma under our tracking and review of the related literature on management of this rare tumor.

Keywords: Waldenstrom Macroglobulinemia (WL); Lymphoplasmacytic Lymphoma (LPL)



  1. Owen RG., et al. “Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia”. Seminars in Oncology 2 (2003): 110-115.
  2. Swerdlow SH., et al. “WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues”. 4th Lyon, France: IARC Press. World Health Organization Classification of Tumoursvolume 2 (2008).
  3. Groves FD., et al. “Waldenstrom’s macroglobulinemia: incidence patterns in the united states, 1988-1994”. Cancer 6 (1998): 1078-1081.
  4. Herrinton LJ and Weiss NS. “Incidence of Waldenstrom’s macroglobulinemia”. Blood10 (1993): 3148-3150.
  5. Bjorkholm M., et al. “Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom macroglobulinemia: a two-institution study”. Seminars in Oncology2 (2003): 226-230.
  6. Dimopoulos MA., et al. “Update on treatment recommendations from the fourth international workshop on Waldenstrom’s macroglobulinemia”. Journal of Clinical Oncology 1 (2009): 120-126.
  7. Itzykson R., et al. “Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobulinemia”. Haematologica5 (2008): 793-794.
  8. Aoki H., et al. “Frequent somatic mutations in D and/or JH segments of ig gene in Waldenstrom’s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but not in common CLL”. Blood 7 (1995): 1913-1919.
  9. Wagner SD., et al. “Similar patterns of Vj gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom’s macroglobulinemia, and myeloma”. Blood 12 (1994): 3647-3653.
  10. Lin P., et al. “Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation”. American Journal of Clinical Pathology 2 (2011): 195-210.


Citation: Himanshu Rohela., et al. “Non Waldenstrom Macroglobulenemia Igg Secreting Lymphoplasmacytic Lymphoma - A Diagnostic Challenge". Acta Scientific Medical Sciences 4.8 (2020): 107-110.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US